Chronic myeloid leukemia Trials in Toronto, Canada
Conditions / Chronic myeloid leukemia / Toronto, Canada
Research into Chronic myeloid leukemia spans multiple therapeutic approaches and trial phases.
19 total trials for this combination
Showing top 10 of 19 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00103844 | Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia | COMPLETED | PHASE2 |
| NCT00101595 | Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | COMPLETED | PHASE2 |
| NCT00261846 | Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias | COMPLETED | PHASE2 |
| NCT01650805 | Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC) | TERMINATED | PHASE3 |
| NCT00574873 | Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML | COMPLETED | PHASE3 |
| NCT01903733 | Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008 | COMPLETED | NA |
| NCT05304377 | A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia | RECRUITING | PHASE1 |
| NCT00375219 | Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation | COMPLETED | PHASE2 |
| NCT00302016 | Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia | NO_LONGER_AVAILABLE | — |
| NCT00101660 | Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib | COMPLETED | PHASE2 |